EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This is a single arm study in the treatment of pancreatic ductal adenocarcinoma (PDAC). The
investigators propose to test the tolerability of chemotherapy plus endoscopic
ultrasound-guided radiofrequency ablation (EUS-RFA) using the RF Electrode in patients
receiving palliative second or third line therapy for unresectable non-metastatic pancreatic
cancer.